A cost-cutting program has been outlined for Merck & Co by its chairman Raymond Gilmartin at a meeting of analysts in New York. Manufacturing costs are to be reduced by between $200 million and $250 million by the end of 1996. Selling and administrative expenses will be cut by around $100 million, he said.
One of the key tasks of the group is to make sure that its acquisition Medco Containment Services earns its keep. Mr Gilmartin also said that Merck has to ensure revenue growth through a series of new product launches. In order to make up for some of the dilution of Merck's earnings per share resulting from the Medco acquisition, the company is planning to repurchase around $2 billion of its shares.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze